Bristol-Myers Squibb news - the latest news from Labiotech.eu

BioGeneration Ventures closes BGV Fund V at €150M

Jim Cornall — Fri, 14 Jul 2023 09:15:00 +0000

BioGeneration Ventures (BGV), an early-stage venture capital company in European biopharma, has closed its BGV V fund at €150 million ($167.9 million), its largest fund since launching its first fund in 2006. BGV V was oversubscribed, with demand from both existing and new investors, with existing investors Eli Lilly and Company, Novo Holdings and Bristol […]

The post BioGeneration Ventures closes BGV Fund V at €150M appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

5 steps to strategic partnerships for healthtech startups

External Contributor — Thu, 02 Mar 2023 11:41:48 +0000

By Varvara Melikhova, founder and CEO of Unison Innovations Strategic partnerships are a better way to build a product’s capabilities than outright acquisitions. While the M&A path is set out for the most mature successful startups, early-stage partnerships can enhance a product’s market value and provide access to Big Pharma expertise and infrastructure, which significantly […]

The post 5 steps to strategic partnerships for healthtech startups appeared first on Labiotech.eu.

Lyvgen and Bristol Myers Squibb commitment to transform cancer care

Liza Laws — Mon, 28 Nov 2022 19:09:36 +0000

Lyvgen Biopharma announced yesterday that it has started a phase 2 trial of LVGN7409 plus docetaxel or, in collaboration with Bristol Myers Squibb, nivolumab in patients with advanced/metastatic non-small cell lung cancer (NSCLC). “Lyvgen clinical collaboration with Bristol Myers Squibb underscores our commitment to exploring combination regimens from our portfolio with complementary mechanisms of action […]

The post Lyvgen and Bristol Myers Squibb commitment to transform cancer care appeared first on Labiotech.eu.

A-Alpha Bio and Bristol Myers Squibb to collaborate on protein degradation

Jim Cornall — Fri, 14 Oct 2022 07:31:15 +0000

A-Alpha Bio, a synthetic biology and machine learning company that measures and engineers protein-protein interactions is to collaborate with Bristol Myers Squibb to discover molecular glue targets for protein degradation. A-Alpha will identify and characterize novel pairs of E3 ubiquitin ligases and targets that Bristol Myers Squibb will utilize for potential design and development of […]

The post A-Alpha Bio and Bristol Myers Squibb to collaborate on protein degradation appeared first on Labiotech.eu.

New research boosts Nordic Bioscience’s PRO-C6 as biomarker assay for trial enrichment in HFpEF

Jim Cornall — Thu, 15 Sep 2022 09:23:25 +0000

The New England Journal of Medicine Evidence (NEJME) has published research that further establishes and positions Nordic Bioscience’s extracellular matrix (ECM) biomarker, PRO-C6, as a potential next-generation biomarker for trial enrichment in patients with heart failure with preserved ejection fraction (HFpEF). The paper is entitled “Endotrophin, a collagen VI formation-derived peptide, in Heart Failure.” The […]

The post New research boosts Nordic Bioscience’s PRO-C6 as biomarker assay for trial enrichment in HFpEF appeared first on Labiotech.eu.

Treatment for adults with moderate to severe psoriasis approved by FDA

Liza Laws — Mon, 12 Sep 2022 16:06:42 +0000

A treatment for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy has been approved by the U.S. Food and Drug Administration (FDA). Bristol Myers Squibb made the announcement today (September 12) that its allosteric tyrosine kinase 2 (TYK2) inhibitor, Sotyku (deucravacitinib) had been approved based on results from a phase […]

The post Treatment for adults with moderate to severe psoriasis approved by FDA appeared first on Labiotech.eu.

Amphista Lands Megadeals to Smash Cancer using Protein Degradation

Jonathan Smith — Thu, 05 May 2022 15:52:23 +0000

As big pharma companies flock to drugs that destroy harmful proteins, the UK protein degradation specialist Amphista Therapeutics has bagged two landmark collaboration deals with the heavyweights Bristol Myers Squibb and Merck. Big pharma companies are piling onto biotechs developing drugs that can cause the destruction of target proteins in the cell — a field […]

The post Amphista Lands Megadeals to Smash Cancer using Protein Degradation appeared first on Labiotech.eu.

BMS’s Cancer Trial Showcases Potential for Checkpoint Inhibitors

Mark Zipkin — Thu, 29 Apr 2021 09:49:22 +0000

Bristol Myers Squibb’s recent phase III success provided the first late-stage confirmation for a novel immune checkpoint target in nearly a decade. This could herald the next generation of checkpoint inhibitors against cancer. Last month, the antibody drug relatlimab, developed by Bristol Myers Squibb, increased the progression-free survival of melanoma patients in phase III. These […]

The post BMS’s Cancer Trial Showcases Potential for Checkpoint Inhibitors appeared first on Labiotech.eu.

Are PD-1 and PD-L1 Checkpoint Inhibitors As Good As We Thought?

Clara Rodríguez Fernández — Mon, 09 Apr 2018 06:45:16 +0000

Checkpoint inhibitors, especially those targeting PD-1 and PD-L1, are exploding in popularity. But how much of it is hype? The pipelines of biotech and pharma are filling up with combination therapies for anti-PD-1 and PD-L1 antibodies. According to the Cancer Research Institute, there are now over 1,500 clinical trials testing the popular checkpoint inhibitors, a dramatical increase […]

The post Are PD-1 and PD-L1 Checkpoint Inhibitors As Good As We Thought? appeared first on Labiotech.eu.

Why did Biotech Beat Pharma to Bring the First Gene Therapy to Market?

Evelyn Warner — Tue, 28 Mar 2017 06:00:27 +0000

Pharma would seemingly best biotech in any competition. A few CEOs explain why it left the honor of “The First Gene Therapy” to biotech. On July 20, 2012, the western world’s first gene therapy, Glybera, received marketing authorization from the EMA. The treatment was designed and developed by uniQure as one-off treatment for Lipoprotein Lipase Deficiency (LPLD), a […]

The post Why did Biotech Beat Pharma to Bring the First Gene Therapy to Market? appeared first on Labiotech.eu.

Will BMS Take Over a Danish Biotech in a Massive €400M Deal?

Melanie De Almeida — Mon, 20 Mar 2017 17:03:35 +0000

Galecto Biotech has presented positive data from a Phase II study with its pulmonary fibrosis candidate, giving BMS the option of take over the biotech. In 2014, Denmark’s Galecto Biotech has signed an option agreement with US-based pharma Bristol-Myers Squibb (BMS) for its lead asset TD139, which is under development for the treatment of pulmonary […]

The post Will BMS Take Over a Danish Biotech in a Massive €400M Deal? appeared first on Labiotech.eu.

French Biotech’s Checkpoint Inhibitor Fails Phase II Leukemia Trial

Clara Rodríguez Fernández — Mon, 06 Feb 2017 10:07:17 +0000

Innate Pharma’s checkpoint inhibitor candidate lirilumab missed its primary endpoint in a Phase II trial, which gave a hard blow to the company’s stock. When the stock market opened this morning, Innate Pharma‘s stock went down by almost 25%. The company had just announced the results of a Phase II trial that failed to prove its […]

The post French Biotech’s Checkpoint Inhibitor Fails Phase II Leukemia Trial appeared first on Labiotech.eu.

The Largest Deals, Fundraising and Exits of 2016 in European Biotech

Clara Rodríguez Fernández — Mon, 26 Dec 2016 07:00:06 +0000

Curious about which technologies have attracted the most cash in biotech finance this year? Here’s a list of the most impressive cash movements of 2016 in Europe. Believe it or not, 2016 has been the worst year for biotech finance in a decade. The political scene has become unfavorable for British biotech after Brexit, and the uncertainty raised by […]

The post The Largest Deals, Fundraising and Exits of 2016 in European Biotech appeared first on Labiotech.eu.

BMS Offers €850M for a British Oncolytic Virus better than CAR-T

Clara Rodríguez Fernández — Thu, 22 Dec 2016 16:15:29 +0000

BMS is offering PsiOxus Therapeutics a massive deal to get exclusive rights of an oncolytic virus that could outperform the promising CAR-T therapies. PsiOxus Therapeutics, based in Oxford, develops immuno-oncolytic viruses to treat solid tumors. Its technology attracted a partnership with Bristol-Myers Squibb earlier this year, which is now offering the British biotech an impressive €850M […]

The post BMS Offers €850M for a British Oncolytic Virus better than CAR-T appeared first on Labiotech.eu.

Microbiomics recruited for Immuno-Oncology in a Huge New Partnership

Clara Rodríguez Fernández — Wed, 16 Nov 2016 13:22:27 +0000

What if the bacteria in your gut could help fight cancer? Enterome is partnering with Bristol-Myers Squibb to explore this possibility and develop microbiome-related therapeutics and diagnostics for immuno-oncology. Enterome, one of the coolest biotechs in Paris, specializes in the isolation of bacteria and microbial targets linked to immune modulation and inflammation. With an impressive […]

The post Microbiomics recruited for Immuno-Oncology in a Huge New Partnership appeared first on Labiotech.eu.

Results from 45% of Clinical Trials are kept Secret

Clara Rodríguez Fernández — Mon, 07 Nov 2016 12:27:41 +0000

A new transparency study has identified Sanofi, Novartis and GSK as the companies that keep the most clinical trial results unreported. TrialsTracker is a tool developed at the University of Oxford that automatically rates transparency on clinical trials by checking if there are results available in clinicaltrials.gov and PubMed. The results: globally, 45% of data on […]

The post Results from 45% of Clinical Trials are kept Secret appeared first on Labiotech.eu.

It’s not over yet for Opdivo; AbbVie takes a stand in Leukemia

Evelyn Warner — Mon, 17 Oct 2016 10:36:58 +0000

The Committee on Medicinal Products for Human Use (CHMP) has handed down a pair of positive opinions of Opdivo and AbbVie’s leukemia therapy in their quests for EMA approval. Before the European Commission reviews an application for market authorization, it crosses the collective desk of the Committee on Medicinal Products for Human Use (CHMP). If […]

The post It’s not over yet for Opdivo; AbbVie takes a stand in Leukemia appeared first on Labiotech.eu.

Big Pharmas Battle to be the Lung Cancer Leader at ESMO

Evelyn Warner — Mon, 10 Oct 2016 15:32:33 +0000

Merck, Roche and BMS have unveiled updated results in Copenhagen as the companies duke it out for the leadership in lung cancer therapies. The conference of the European Society of Medical Oncology (ESMO) is underway in Copenhagen, and big pharma’s efforts to cure lung cancer are stealing the show. Three titans, Roche (Genentech), Merck and […]

The post Big Pharmas Battle to be the Lung Cancer Leader at ESMO appeared first on Labiotech.eu.

BMS to acquire Swedish Immuno-Oncology Biotech for €460M

Denise Neves Gameiro — Thu, 07 Jul 2016 09:11:00 +0000

Bristol-Myers Squibb wants to strengthen its immuno-oncology even further. For this, it is acquiring Cormorant – a Biotech developing immunotherapies in a deal that could go up to €460M. Based at the Karolinska Institute Science Park in Stockholm (Sweden), Cormorant was a private Biotech focusing on cancer immunotherapies. Its main program was HuMax-IL8, which is currently in Phase […]

The post BMS to acquire Swedish Immuno-Oncology Biotech for €460M appeared first on Labiotech.eu.

BMS to combine Immuno-Oncology Blockbuster with Oxford Biotech

Dani Bancroft — Fri, 01 Jul 2016 12:27:55 +0000

Oxfordshire based PsiOxus will team up with the Immuno-Oncology Giant, Bristol-Myers Squibb, to test the combinatorial effect of their blockbuster drug with an Oncolytic viral therapy in late-stage cancer patients. Together they will evaluate the safety, tolerability, and preliminary efficacy of PsiOxus’ Enadenotucirev, a systemically administered oncolytic adenovirus therapeutic, in combination with Bristol-Myers Squibb’s Opdivo blockbuster (nivolumab), which […]

The post BMS to combine Immuno-Oncology Blockbuster with Oxford Biotech appeared first on Labiotech.eu.